Predictive Oncology narrows Q3 net loss 22% to $3.2M; revenue rises 57% to $715K

Axe Compute Inc.

Net loss of $3.2M ($0.78 per share) vs $4.1M ($1.04) in Q3 2022, a 22% reduction.
Revenue of $715,056, up 57% YoY, driven by higher sales of 3-D models.
Gross margin improved to 85% from 76%; G&A expenses decreased $704K to $2.58M.
Cash and equivalents $11.9M (down from $22.1M at Dec 31, 2022); equity $11.7M.
Milestone: accurately predicted cancer types responsive to CRH's glutaminase inhibitors; ovarian cancer study with UPMC.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Axe Compute Inc. reported three months ended September 30, 2023 results: revenue $715,056, EPS $0.78.

Period: three months ended September 30, 2023
Revenue: $715,056
EPS: $0.78
Result: reported results

Exact text from the filing

Predictive Oncology recorded revenue of $715,056 in the third quarter of 2023

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

Axe Compute Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-007073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.